Meeting
2017 ASCO Annual Meeting
Phase I/II study of an implantable device delivering low intensity pulsed ultrasound (LIPU) to disrupt the blood-brain barrier (BBB) followed by intravenous carboplatin chemotherapy in patients with recurrent glioblastoma (GBM).
Authors
Ahmed Idbaih
Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France
Ahmed Idbaih , Michael Canney , Alexandre Vignot , Bruno Law-Ye , Caroline Dehais , Caroline Houillier , Florence Laigle-Donadey , Jean-Yves Delattre , Alexandre Carpentier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02253212
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2034)
DOI
10.1200/JCO.2017.35.15_suppl.2034
Abstract #
2034
Poster Bd #
276
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Safety and preliminary efficacy data from a phase I study of an implantable low intensity pulsed ultrasound (LIPU) device for disrupting the blood-brain barrier (BBB) in patients treated by chemotherapy for recurrent glioblastoma (GBM).
First Author: Ahmed Idbaih
Poster
2021 ASCO Annual Meeting
A phase I/IIa study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin.
First Author: Ahmed Idbaih
Poster
2022 ASCO Annual Meeting
Repeated opening of the blood-brain barrier with the skull-implantable SonoCloud-9 (SC9) device: Phase 1 trial of nab-paclitaxel and SC9 in recurrent glioblastoma.
First Author: Adam M. Sonabend
Poster
2021 ASCO Annual Meeting
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
First Author: Andrew E. Sloan